FORIGERIMOD

Investigational

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22356680 | https://clinicaltrials.gov/ct2/show/NCT03427151

Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.

Approval Year

PubMed

Title	Date	PubMed
A general preparation of protected phosphoamino acids.	2012-03-02	22356680

Sample Use Guides

In Vivo Use Guide

200 mcg of IPP-201101 (FORIGERIMOD) will be administered subcutaneously every 4 weeks for 24 weeks.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Mon Mar 31 21:19:52 GMT 2025` Edited by `admin` on `Mon Mar 31 21:19:52 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	1JRB6UKG4Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IPP-201101

Preferred Name

English

FORIGERIMOD

Official Name

English

forigerimod [INN]

Common Name

English

RIGERIMOD

Common Name

English

L-TYROSINE, L-ARGINYL-L-ISOLEUCYL-L-HISTIDYL-L-METHIONYL-L-VALYL-L-TYROSYL-L-SERYL-L-LYSYL-L-ARGINYL-O-PHOSPHONO-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-ARGINYLGLYCYL-L-TYROSYL-L-ALANYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-

Common Name

English

FORIGERIMOD [USAN]

Common Name

English

Forigerimod [WHO-DD]

Common Name

English

IPP201101

Code

English

Code System Code Type Description

FDA UNII

1JRB6UKG4Q